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eQTL on NAFLD  risk was  further  tested  in  three  independent  populations. We  found  that  rs139051 did not
independently affect the NAFLD risk, whilst rs738409 did not significantly modulate PNPLA3 transcription but
was  associated with NAFLD  risk.  The A‐G  haplotype  associated with  higher  transcription  of  the  disease‐risk
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INTRODUCTION 
 
Affecting over 30% of the U.S. population, non-
alcoholic fatty liver disease (NAFLD) is the most 
common cause of chronic liver disease [1-3]. NAFLD 
starts with hepatosteatosis, and can progress to non-
alcoholic steatohepatitis (NASH), cirrhosis and 
hepatocellular carcinoma (HCC) [1-3]. While the 
etiology of NAFLD still remains incompletely 
understood, the development of NAFLD has been 
strongly related to age, energy homeostasis and genetic 
predisposition [4-6]. In recent years, genome-wide 
association studies (GWAS) have identified a number 
of loci conferring risk for NAFLD. Among these, the 
rs738409 C>G (I148M) variant of the patatin like 
phospholipase domain containing 3 (PNPLA3) gene 
located at 22q13 is the most well validated association, 
influencing degree of steatosis, grade of inflammation, 
stage of fibrosis and risk of HCC [7-11]. However, the 
detailed mechanism underlying this genetic association 
remains incompletely understood [10]. In particular, the 
biological consequences of this mutation and how it 
plays a causal role in disease pathogenesis are still 
unclear. Previous in vitro study demonstrated that 
PNPLA3 plays a role in triglyceride metabolism as a 
lipase and the 148M alteration disrupts its hydrolysis 
activity [12]. Other studies indicated that 148M variants 
may also reduce triglyceride secretion as well as 
promotes triglyceride synthesis by increasing its 
lysophosphatidic acid acetyltransferase (LPAAT) 
activity [13-15]. In further exploring this mechanism, 
many studies have focused on various animal models. 
Thus far, it has been consistently shown that neither 
overexpression (transgenic or Tg mouse) nor loss-of-
expression (knock-out or KO mouse) of the wild-type 
(WT) Pnpla3 gene induces a NAFLD phenotype in 
mice (16-18). However, overexpression of the variant 
form, human PNPLA3148M (Tg mouse), does lead to 
hepatosteatosis [18]. This observation is further 
confirmed in a 148M knock-in (KI) mouse model, in 
which physiologically regulated background expression 
of Pnpla3148M on a normal chow diet does not produce 
NAFLD, whilst increased Pnpla3148M expression 
following consumption of a high-sucrose diet does 
induce NAFLD [19]. These features parallel the effect 
of a PNPLA3 catalytic activity-negative mutant, S47A 
[18, 19]. These studies strongly suggest a “dominant-
negative” mechanism underlying the PNPLA3148M 
pathogenesis. While the high transcriptional expression 
of the mutant allele seems to be required for this 
pathogenic effect in animals, it remains unclear whether 
there is a similar mechanism in humans. As the level of 
PNPLA3 expression in humans is variable, it is 
conceivable that inter-individual differences in PNPLA3 
gene expression further modify the risk for NAFLD 
attributed to the 148M variant. Clarifying this 
mechanism would be essential for establishing 
therapeutic strategies for NAFLD/NASH. Interestingly, 
a recent study pointed out that a nonsynonymous 
common variant rs2294918 (E434K) seemed to be 
associated with decreased PNPLA3 transcription, which 
may modified the effect of rs738409 in NAFLD [20]. 
However, detailed knowledge about the regulation of 
hepatic PNPLA3 gene transcription in human 
populations is extremely limited. To date, no study has 
been conducted that fully investigates the inter-
individual variability in hepatic PNPLA3 expression as 
well as its impact on NAFLD risk.  
 
In order to better understand the transcriptional 
regulation of PNPLA3 in human liver, we performed an 
eQTL (gene expression quantitative trait loci) mapping 
for PNPLA3 mRNA expression in human liver tissue 
samples, using genome-wide transcriptome and 
genotypic data that we have collected in our previous 
study [21]. We further studied the relationship between 
rs738409 and PNPLA3 gene expression, and 
investigated the association between significant eQTLs 
and NAFLD. The combined haplotypic effect of the 
significant eQTL and rs738409 in conferring NAFLD 






Studying genotypic data of 620,900 SNPs as well as 
imputed genotypic data (in total over 3.9 million SNPs 
using HapMap release 27 as reference), we focused our 
analysis on identification of cis-acting eQTLs on 
chromosome 22. We found that the most significant 
eQTLs were mapped to the PNPLA3-SAMM50 region 
(Fig. 1A-B). Two SNPs, rs139051 (51bp upstream of 
rs738409 in intron 2, and 28bp away from the intron-
exon boundary) and rs2294918 (E434K in exon 9) were 
identified as the most significant cis-acting eQTLs for 
PNPLA3 transcription [p = 6.6×10-8 and 2.4×10-7, 
respectively; false discovery rate (FDR) < 0.05 for both] 
(Fig. 2A-B).  
 
Detailed linkage disequilibrium (LD) analysis of 
variants across the locus revealed that whilst rs139051 
was in low LD with all other significant eQTLs (r2 ≤ 
0.50 for all tests), rs2294918 was in high LD with the 
remaining eQTLs (r2 ≥ 0.80), suggesting an independent 
role of rs139051. The plotted data indicated that the A 
allele of rs139051 and G allele of rs2294918 were 
associated with increased PNPLA3 gene expression 
(Fig. 2A, Fig. 2B). In contrast, after correcting for 
multiple testing, the rs738409 polymorphism was not a 
significant eQTL for hepatic PNPLA3 expression (FDR 
> 0.05) (Fig. 2C).  





























We further analyzed the inter-dependence of rs139051, 
rs2294918 and rs738409 in altering PNPLA3 gene 
expression. Analysis of the HapMap data (CEU, 
Northern Europeans in Utah) demonstrated that, 
although there is low LD among these three SNPs as 
measured by the r2 values (r2 ≤ 0.26 for all), the D’ 
values (coefficient of linkage disequilibrium) (D’=0.61, 
0.88 and 1 between rs139051 and rs738409; between 
rs139051 and rs2294918; and between rs738409 and 
rs2294918, respectively) suggested alleles of these 
SNPs may share the same haplotype(s). Similar data 
(low r2 but relatively high D’ values) were observed in 
both Asian (CHB+JPT, Han Chinese in Beijing and 
Japanese in Tokyo) and African (YRI, Yoruba in 
Ibadan, Nigeria) populations (data not shown). The 
phased HapMap haplotypic data (CEU) suggest that the 
rs139051A and rs2294918G alleles (both of which are 
associated with increased PNPLA3 expression) are 
almost always co-segregated in the same haplotype 
(data not shown). Further multivariate haplotypic 
association with gene expression in liver tissue 
demonstrated that the association between the 
rs2294918 G allele and PNPLA3 expression was 
actually driven by the rs139051 A allele. In rs139051 
G/G homozygous individuals, rs2294918 genotypes did 
not significantly contribute additional variability in gene 
expression, which was in contrast with the association 





























among the rs2294918 A/A homozygous individuals 
(Fig. 2D). Similarly, the association between rs139051-
rs738409 diplotypes and the PNPLA3 mRNA 
expression also suggested that rs139051 solely 
contributed to gene expression (Fig. 2E). The 
independent role of rs139051 in association with gene 
expression was further verified in a multivariate 
analysis in which, after controlling for rs139051 
genotype, none of the other eQTLs at the locus 
remained significant (p > 0.05 for all tests, data not 
shown), while after conditioning all other SNPs, 
rs139051 remained significant (p = 8.18×10-6). Taken 
together, these data suggest a potential causal role of 
rs139051 in regulating hepatic PNPLA3 transcription. 
 
Validation of the rs139051 as a significant eQTL 
 
To confirm the association between rs139051 and 
PNPLA3 mRNA expression, we used another set of liver 
samples among which genome-wide transcriptome data 
has been previously collected in a subset of samples (N = 
54) [22]. These samples were collected from bariatric 
surgery of obese patients in Caucasian origin [22]. We 
found that again, rs139051 rather than rs738409 was 
significantly associated with PNPLA3 transcription (p = 
0.037 for rs139051; p = 0.95 for rs738409). After 
controlling for age, gender and BMI, this association at 
rs139051 remained significant (p = 0.029). 
















































Electrophoresis mobility shift assay (EMSA)  
 
In order to further explore the potential causal role of 
rs139051, we performed an EMSA to examine the 
potential interaction between the SNP sequence and 
hepatic nuclear factors. We found that rs139051 
exhibited an allele-specific binding to nuclear proteins 
extracted from the HepG2 cell line, with the rs139051 A 
allele possessing significantly higher (> 2 fold) affinity 
to nuclear factor(s) compared to the G allele (p = 
0.017). This allelic binding specificity to nuclear protein 
was supported by a much weaker signal in the reaction 
with proteins extracted from the cytoplasm as compared 











































that this binding is between the DNA and a nuclear-
specific protein rather than a cytoplasmic protein that 
may non-specifically bind to DNA.  
 
Association between SNPs and NAFLD 
 
To test whether rs139051 or rs2294918 contributes to 
NAFLD risk, we performed association analyses 
between rs139051, rs2294918 as well as rs738409 and 
NAFLD phenotypes in a large cohort of European 
Caucasian NAFLD patients with histologically 
characterized disease collected by the FLIP Consortium 
(N = 949). Consistent with previous studies [23], 
rs738409 was significantly associated with histological 
Figure 2. Regulatory role of rs139051  in PNPLA3 mRNA expression  in human  liver. (A‐C) Correlations between
rs139051 (p = 6.6×10‐8, FDR < 0.05), rs2294918 (p = 2.4×10‐7, FDR < 0.05) and rs738409 (p = 0.04, FDR > 0.05) genotypes and
PNPLA3  gene  expression.  (D)  The  dependence  of  rs139051  and  rs2294918  in  association  with  PNPLA3  expression.  No







www.aging‐us.com  30  AGING (Albany NY) 
disease severity across key quantitative phenotypes 
including degree of steatosis (p = 1.1×10-13), NAFLD 
Activity Score (NAS, the sum of the scores for 
steatosis, hepatocyte ballooning degeneration and 
lobular inflammation and reflects disease activity) (p = 



















































justing for relevant covariates (age, BMI and presence 
of type 2 diabetes mellitus). A less strong but 
statistically significant association between rs139051 
and steatosis (p = 1.8x10-4), steatohepatitis (p = 2.1x10-
4) but not fibrosis (p = 0.435) was also observed. 



















































Figure  3.  Electrophoretic  mobility  shift  assay  (EMSA)  for  the  rs139051  polymorphism.  (A)  Representative
demonstration of EMSA assay  for  rs139051 sequence  from  three  independent  replications. Relative binding efficiency  to
nuclear extracts of the HepG2 cells between the A allele and G allele probes were shown (lane 1 and 3). The DNA‐protein
complex diminished in the reactions with 200X non‐labeled competitor probes (lane 2 and 4). The interaction complex was







† Added Value (95%CI)# P
# P* Beta‡ P‡ 
Steatosis (1-4) 
A-G 0 - 9.85 x10-7 0.33 3.36x10-11 
G-G -0.08 (-0.31, 0.16) 0.51 3.78 x10-4 0.23 0.0014 
A-C -0.46 (-0.65, -0.28) 9.85 x10-7 - -0.15 0.0108 
G-C -0.46 (-0.60, -0.32) 1.33 x10-11 0.96 -0.23 3.15x10-8 
NAS (1-9) 
A-G 0 - 4.81 x10-4 0.56 4.27x10-8 
G-G -0.06 (-0.17, 0.05) 0.30 0.05 0.27 0.06 
A-C -0.16 (-0.25, -0.07) 4.81 x10-4 - -0.15 0.2 
G-C -0.18 (-0.25, -0.12) 2.66 x10-8 0.61 -0.4 2.45x10-6 
Fibrosis (1-7) 
A-G 0 - 0.04 0.17 0.01 
G-G 0.11 (-0.04, 0.27) 0.15 9.64 x10-4 0.32 0.0013 
A-C -0.14 (-0.28, -0.008) 0.04 - -0.15 0.06 
G-C -0.12 (-0.22, -0.03) 0.0089 0.74 -0.17 0.0092 
†Haplotype frequencies across entire NAFLD cohort: A‐G 0.2425; G‐G 0.09797; A‐C 0.1628; G‐C 0.4968. Estimated r2 
between rs139051 and rs738409 = 0.20.   #Tests  for the effect of each haplotype compared to A‐G.  *Tests  for the 
effect of each haplotype compared to A‐C. ‡Tests for the effect of each haplotype compared to all other haplotypes 
combined.  *NAFLD  histologically  characterized  using  the  semi‐quantitative  NASH  CRN  Score  (34).  The  NAFLD 
Activity  Score  (NAS) equals  the  sum of  the  scores  for  steatosis, hepatocyte ballooning degeneration and  lobular 
inflammation and reflects disease activity.   
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with steatosis (p = 2.1x10-5), steatohepatitis (p = 2.8x10-
4) and fibrosis (p = 0.01). However, in the multivariate 
analysis conditioning on the rs738409 genotype, neither 
rs139051 nor rs2294918 was significantly associated 
with these phenotypes (p > 0.05 for all tests), suggesting 
that neither rs139051 nor rs2294918 is independent of 
rs738409 as a risk factor for NAFLD.  
 
To investigate further whether rs139051 or rs2294918 
modifies the effect of rs738409 alleles in contributing to 
NAFLD risk, we tested associations between the 
rs139051-rs738409 or rs2294918-rs738409 haplotypes 
and aforementioned phenotypes. However, analyses 
examining the relative contribution of each SNP to the 
overall haplotype effect did not identify a statistically 
significant independent effect of rs139051 or rs2294918 
in the FLIP population. Indeed, the carriage of the A-G 






































rs139051 A allele and the disease-risk rs738409 G 
(148M) allele, conferred similar risk for NAFLD 
phenotypes as compared to the G-G haplotype which 
contains the rs738409 risk allele, but possesses a 
relatively lower expression level (p = 0.51) (Table 1 for 
rs139051 and Table 2 for rs2294918).  
 
To further verify these observations in an independent 
sample, we performed similar analysis in the 
aforementioned bariatric patient cohort (N = 212) in 
which quantitative pathological evaluation of NAFLD 
phenotypes has previously been described [22, 24, 25]. 
Given the dependence of rs2294918 on rs139051 as a 
significant eQTL, we did not include rs2294918 in the 
following analyses. Again, rs738409 but not rs139051 
was significantly associated with NAFLD in the 
univariate analysis (p = 2.0×10-4 and 0.093, respective-







































human and mouse. Transcriptional variability of 148I  isoform does not  lead to hepatosteatosis. Very  low expression of
148M  isoform  in mice due  to  the  low baseline Pnpla3 expression does not  induce steatosis as well. However,  increased
expression of PNPLA3148M in mice or a higher baseline transcriptional level of PNPLA3148M in humans leads to steatosis. This
highlights the “dominant‐negative” effect of the 148M allele in both species. Tg = transgenic, KO = knockout, KI = knockin. 
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rs139051 and NAFLD phenotypes was observed after 
conditioning on rs738409 and adjusting for age, gender 
and BMI. Also, no significant difference between A-G 
and G-G haplotypes in conferring risk for NAFLD or 
influencing NAFLD histological features was observed 
(Table 3). In a subset of 54 samples in which the 
PNPLA3 mRNA level was measured, we examined if 
the PNPLA3 mRNA expression is a direct co-factor 
modifying the genetic effect of rs738409 on NAFLD. 
We found that the PNPLA3 mRNA level was not 
significantly associated with any of the NAFLD 
phenotypes (p > 0.05 for all tests) (data not shown). The 
PNPLA3 mRNA level did not significantly modify the 
risk of NAFLD conferred by rs738409 (main effect of 
PNPLA3 mRNA level on NAFLD p = 0.61; interaction 
between rs738409 and PNPLA3 mRNA level with 
respect to NAFLD (p = 0.97). 
 
In order to expand our observations to other ethnic 
groups, we further tested the genetic association in a 
Han Chinese NAFLD patient (N = 384) and healthy 
control (N = 384) population with matched age and 
gender that are reported in our previous study [26]. 
After adjusting for age and BMI, both rs738409 and 
rs139051 were individually associated with 
sonographically detected NAFLD (p = 2.0×10-4 and 
1.3×10-3, respectively). Once again, after controlling for 
rs738409, rs139051 was no longer associated with 



























rs139051-rs738409 haplotypes and NAFLD, we again 
found that the A-G and G-G haplotypes confer similar 
risk of NAFLD (p = 0.27) (Table 3). 
 
Given that the rs738409 G allele was consistently 
demonstrated to be significantly associated with 
increased risk for NAFLD phenotypes in all three 
cohorts, the rs738409 C allele was correspondingly 
significantly associated with reduced risk. We 
investigated whether rs139051 modifies this protective 
effect of the rs738409 C allele. Again, no statistical 
significance was found between the A-C and G-C 
haplotypes in conferring the reduced risk for NAFLD in 




The causal mechanism of PNPLA3148M for NAFLD 
remains incompletely understood. While high 
expression level of the mutant isoform is critical for the 
induction of the phenotype in animals, it is not clear 
whether inter-individual difference in PNPLA3 
expression in humans would modify the pathogenic 
effect of the 148M mutant. In this study, we for the first 
time comprehensively investigated the genetic control 
of the PNPLA3 transcriptional variability in human 
livers. We describe a novel genetic variant significantly 
influencing hepatic mRNA expression of PNPLA3 that, 


































† Added Value (95%CI)# P# P* 
Steatosis (1-4) 
G-G 0 - 1.921e-10 
A-G -0.62 (-1.59,   0.36) 0.24 0.73 
G-C -0.44 (-0.58, -0.30)      1.921e-10 - 
A-C -0.45 (-0.58, -0.32)      6.281e-12 0.96 
NAS (1-9) 
G-G 0 - 4.06e-06 
A-G -0.16 (-0.64, 0.33)       0.53 1 
G-C -0.16 (-0.22, -0.09)     4.06e-06 - 
A-C -0.17 (-0.23, -0.10)      1.39e-07 0.77 
Fibrosis (1-7) 
G-G 0 - 0.004 
A-G 0.24 (-0.39, 0.86)       0.46 0.22 
G-C -0.15 (-0.25, -0.05)     0.0036 - 
A-C -0.17 (-0.26, -0.07)     0.00036 0.72 
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differences in PNPLA3 transcription in human livers. 
Capitalizing upon knowledge of this eQTL, we studied 
whether the pathophysiological effect of the non-
synonymous rs738409 (I148M) variant is solely 
attributed to the amino acid change or whether 


















































as it appears to be in mice. Our analyses suggest that 
PNPLA3 gene expression does not significantly modify 
the risk for NAFLD in humans. 
 
Our data clarifies a number of critical points raised by 

























































† Added Value (95%CI)# P
# P* Beta‡ P‡  Pa Pb Pc 
Steatosis    
(0-3) 
A-G 0 - 0.0061 0.41 0.0013 
0.00017 0.90 0.26 
G-G 0.14 (-0.39, 0.67) 0.60 0.0087 0.63 0.0072 
A-C -0.52 (-0.90, -0.15) 0.0061 - -0.22 0.077 
G-C -0.42 (-0.68, -0.16) 0.0020 0.53 -0.21 0.033 
NAS (0-8) 
A-G 0 - 0.016 0.48 0.0017 
0.00012 0.74 0.54 
G-G 0.11 (-0.32, 0.54) 0.63 0.020 0.68 0.015 
A-C -0.38 (-0.69, -0.07) 0.016 - -0.22 0.13 
G-C -0.33 (-0.55, -0.12) 0.0029 0.72 -0.25 0.030 
Fibrosis  
(0-4) 
A-G 0 - 0.53 0.12 0.18 
0.01 0.92 0.57 
G-G 0.27 (-0.27, 0.80) 0.33 0.10 0.42 0.010 
A-C -0.16 (-0.66, 0.34) 0.53 - -0.027 0.76 
G-C -0.33 (-0.72, 0.07) 0.12 0.51 -0.13 0.065 
NAFLD 
A-G 0 - 0.064 0.87 0.0043 
0.0018 0.61 0.97 
G-G 0.69 (-0.71, 2.10) 0.31 0.019 1.73 0.014 
A-C -0.66 (-1.36, 0.04) 0.064 - -0.17 0.52 





CRN  Score  [34].  The  NAFLD  Activity  Score  (NAS)  equals  the  sum  of  the  scores  for  steatosis,  hepatocyte 
ballooning  degeneration  and  lobular  inflammation  and  reflects  disease  activity.  aTest  for  main  effect  of 
rs738409; bTest for main effect of mRNA level; cTest for Interaction between mRNA level and rs738409. 
Table  4.  Association  between  rs139501‐rs738409  haplotypes  and  NAFLD  in  the  Han 
Chinese cohort (N = 768, with case : control = 1:1). 
 
Haplotype† Relative OR (95%CI)# P
# P* Overall OR‡ P
‡ 
A-G 1.0 (ref) - 0.018 1.53 1.37x10-4 
G-G 0.39 (0.07, 2.17) 0.27 0.46 0.49 0.41 
A-C 0.73 (0.56, 0.95) 0.018 - 0.92 0.52 
G-C  0.63 (0.50, 0.80)  1.01x10-4 0.29 0.72 0.002 
†  Haplotype  frequencies  across  entire  population:  A‐G  0.371;  G‐C  0.379;  A‐C  0.245;  G‐G  0.005. 
Estimated  r2  between  rs139051  and  rs738409  =  0.35.  #Tests  for  the  effect  of  each  haplotype 
compared to A‐G. *Tests for the effect of each haplotype compared to A‐C. ‡Tests for the effect of 
each haplotype compared to all other haplotypes combined. 
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not yet clarified in humans. Studies in animal models 
have demonstrated that: 1) The pathogenic role of the 
148M allele is not via altering the PNPLA3 
transcription. Knockin (KI) of the 148M allele into the 
mouse Pnpla3 gene did not cause a significant change to 
the gene expression [19]. 2) Variability in wild-type 
PNPLA3 transcription alone does not contribute to the 
fatty liver phenotype. The mice models with either 
knockout PNPLA3 [16, 17] or overexpression of the 
wild-type PNPLA3 [18] did not lead to fatty liver. 3) 
An increased transcription of the PNPLA3148M is 
required for the induction of hepatosteatosis in mice. In 
the transgenic mouse model created by Li et al., 
overexpression of the PNPLA3148M mutant form in 
the liver under normal chow diet feeding successfully 
induced hepatic steatosis. Meanwhile, in the recent 
148M-KI model study, hepatic fat accumulation was 
produced only when the expression of the Pnpla3148M 
isoform was induced [19]. 4) There seems to be a strong 
gene-environment interaction in the PNPLA3148M 
function in mice. The PNPLA3 transcription can be 
significantly induced by nutritional stimuli, especially 
carbohydrates [27-31]. It was shown that in the 
PNPLA3148M Tg mice, high sucrose-diet feeding as a 
stimuli for PNPLA3 transcription exacerbates the 
phenotype [18]. Furthermore, in the KI model, Pnpla3 
was up-regulated by increased carbohydrates intake 
(high-sucrose diet feeding), which leads to fatty liver 
[19]. In contrast, the interaction between high fat diet 
and PNPLA3 genotype is less significant. While high 
fat diet feeding can significantly increase PNPLA3 
protein level in the liver, it does not alter the PNPLA3 
transcription [27]. There is also no difference in hepatic 
fat accumulation in mice carrying different genotype at 
the 148 position [18, 19]. These findings indicate that in 
mice, the pathogenic role of Pnpla3148M significantly 
depends on the high level of hepatic expression of this 
gene, and this effect may be further augmented by 
environmental factors especially carbohydrate intake.  
 
Our study in humans confirmed some of these 
observations in mice. First, we show that carriage of the 
rs738409 G allele does not alter PNPLA3 transcription 
in humans, suggesting that, as in mice, the effect of the 
rs738409 variant in humans is more likely related to the 
functional impact of the amino acid substitution rather 
than any quantitative effect on gene expression. This 
assertion is further supported by reports that 148M 
directly alters the enzymatic activity of PNPLA3 [12, 
18]. Second, our data demonstrated that variability in 
PNPLA3 transcription alone does not contribute to the 
risk of fatty liver or disease severity. In our samples, the 
PNPLA3 mRNA level was neither associated with 
NAFLD nor with the degree of steatosis. Furthermore, 
we identified that the rs139051 variants as a strong 
eQTL plays an independent role in regulating PNPLA3 
transcription in man. However, after controlling for 
rs738409, rs139051 was neither significantly associated 
with NAFLD, nor with disease severity in any of the 
populations studied.  
 
On the other hand, we also observed significant 
differences in the pathogenic effect of PNPLA3 
between human and mouse. First, our study indicates 
that the pathogenic function of the PNPLA3148M 
isoform in humans does not rely on the transcriptional 
variability. The apparent changes in hepatic PNPLA3 
expression due to rs139051 carriage do not modify the 
effects of rs738409 G-allele carriage in promoting 
NAFLD and related phenotypes. This is supported by 
the analysis of associations between rs139051-rs738409 
haplotypes and histological features of NAFLD. While 
the A-G haplotype represents a higher expression level 
of the disease risk allele than the G-G haplotype, there 
is no significant difference between these two 
haplotypes in conferring risk to NAFLD or disease 
severity (Table 1-3). A similar effect was observed 
between the A-C and G-C haplotype in conferring 
reduced risk for NAFLD. Moreover, the multivariate 
analysis using PNPLA3 mRNA level as either a direct 
covariate or an interacting effect in the bariatric liver 
samples did not show a modification for the NAFLD 
risk attributed to the rs738409 G-allele (Table 2). Taken 
together these results suggest that the absolute PNPLA3 
expression levels has a lesser effect in human NAFLD 
as compared to that in mice. Second, it seems that the 
regulatory role of rs139051 remains significant even in 
the livers of obese patients undergoing bariatric surgery, 
suggesting that metabolic conditions under obesity do 
not overtake the genetic effect of rs139051. Moreover, 
the association between rs139051-rs738409 haplotypes 
and NAFLD or NAFLD severity was also not modified 
in the obese population, further suggesting that 
environment-gene interaction plays a minimal effect on 
the PNPLA3148M pathogenesis in humans as well.  
 
The divergence between our findings in humans and 
what have observed in animal models may reflect a 
fundamental difference in disease pathogenesis between 
species, and highlights the limitations of using animal 
models in recapitulating human pathophysiology. Given 
the differences in diet and other environmental factors 
between human and mouse, it is possible that the two 
species are under different selection pressure during 
evolution, which further leads to differential 
transcriptional regulation of hepatic genes. Indeed, the 
PNPLA3 gene undergoes a higher baseline hepatic 
expression in humans than in mice. This has been 
demonstrated in recent studies that the PNPLA3 mRNA 
expression is highly expressed in human livers [27], 
while in normal chow diet-fed wild-type mice, the 
hepatic Pnpla3 mRNA level is extremely low (in 
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C57BL/6 and LDLR−/− mice) [32] or even 
undetectable (in SWISS mice) [33]. As a result, the 
higher baseline expression of PNPLA3 in most human 
liver may already be sufficient for the pathogenic 
function of the 148M form, and additional regulation of 
PNPLA3 in humans by either variant alleles or other 
environmental factors therefore would not be necessary. 
Notably, based on the frequency of rs139051-rs738409 
haplotypes calculated in Tables 1-4 (see footnotes of the 
Tables), the A-G haplotype respectively accounts for 
over 70% and almost 99% of all haplotypes containing 
the rs738409 G allele in Western populations (71.3% in 
FLIP and 76.7% in FLPGP cohort) and in Chinese, 
suggesting that the majority of individuals carrying the 
rs738409G allele actually also have an increased 
PNPLA3 transcription level. Furthermore, the 
discrepancies between the two species may also reflect 
the distinct dependence on the pathways in lipid 
homeostasis between the two species. PNPLA3 
expression in humans is dominated by the liver 
followed by skin and adipose tissue [27], while in mice, 
Pnpla3 has the highest expression in adipose tissue [32], 
indicating that hepatic PNPLA3 plays a more important 
role in human lipid metabolism than in mice. Therefore, 
hepatic lipid homeostasis in humans may be more 
sensitive to the effect of PNPLA3148M. It is thus very 
possible that the prevalence of the rs738409 in human 
population is actually a protective mechanism with 
which accumulation of lipids in the liver, especially 
during malnutrition or other environmental conditions, 
is highly beneficial. Nevertheless, these data together 
still indicate that a considerable level of hepatic 
expression of the PNPLA3148 is essential for the 
induction of fatty liver, though a “pathogenic 
transcriptional threshold (i.e. the transcriptional level 
that is sufficient for the expression of the pathogenic 
effect of 148M)” remains unknown. The similarity and 
difference in the PNPLA3148 pathogenesis between 
human and mouse were summarized in Fig 4. 
 
We note that rs2294918 has been associated with 
PNPLA3 gene expression in human liver and was 
reported to confer additional risk for NAFLD and 
NASH independent of rs738409 in a recent study by 
Donati et al [20]. However, a comprehensive locus-
wide eQTL mapping in our study has excluded the 
causal role of rs2294918 on altering the PNPLA3 
transcription. Also, our conditioning analyses have 
excluded the independent effect of either rs139051 or 
rs2294918 on disease risk across multiple populations. 
The discrepancies between Donati’s study and our 
findings could be due to the differences in population 
that were studied (Italian populations by Donati et al. 
vs. mixed European or American Caucasians and 
Chinese in our study), sample size (our study cohort, 
although substantial, was slightly smaller), or 
phenotypes to be investigated (NAFLD or NASH for a 
case-control design in Donati et al. as compared to a 
quantitative trait analysis on disease severity in our 
study). Notably, given the low frequency of the G-G 
haplotype in both Caucasian and Chinese populations as 
mentioned above, it is possible that the sample size was 
not sufficient to distinguish the moderate difference in 
the contribution of disease risks between the A-G and 
G-G haplotype. These possibilities thus warrant further 
study of this question in larger cohorts of NAFLD 
patients that are uniformly phenotyped, and among 
different ethnic groups.  
 
In conclusion, our study revealed a genetic basis 
underlying variation in human hepatic PNPLA3 
transcription. Using this information, our study further 
clarified the role of this variation, as well as its impact 
on the established role of the 148M variant in NAFLD 
susceptibility. The apparent divergence between our 
results and what has previously been reported in animal 
models highlights the complexity underlying the role of 
the PNPLA3148M variant in the development of 
NAFLD and potentially offers important new insights 
into the consequent pathogenic mechanisms both in 
mice and humans. 
 




This study consists of samples obtained from several 
sources and parent studies as described below.  Samples 
were collected with written informed consent obtained 
from participants with approval of institutional review 
boards (IRBs) at each participating institution. The 
Purdue University IRB has approved the use of the liver 
samples for the purpose of this study (approval number 
1202011870). The study was carried out in compliance 




FLIP samples: A cohort of 949 unrelated patients of 
European-Caucasian descent with histologically 
characterized NAFLD representing the full spectrum of 
disease from simple steatosis through steatohepatitis to 
advanced fibrosis and cirrhosis was assembled from 
centers across Europe as part of a GWAS study by 
members of the FLIP consortium. The study had the 
necessary ethical approvals in all recruiting centers and 
all participants gave informed consent. Alternative 
diagnoses were excluded, including excess alcohol 
intake, chronic viral hepatitis (hepatitis B and hepatitis 
C), autoimmune liver diseases, hereditary hemochroma-
tosis, α1-antitrypsin deficiency, Wilson’s disease and 
drug induced liver injury. 
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Bariatric NAFLD samples: The samples (N = 212) were 
collected under a study protocol that had been 
previously reviewed and approved by the Medical 
College of Wisconsin's Institutional Review Board.  
Each participating subjected gave a written Informed 
consent for participation. Subjects were of northern 
European descent, morbidly obese (BMI ≥ 40 kg/m2 or 
> 35 kg/m2 with significant comorbidities) and prior 
unsuccessful attempts to lose and maintain weight, who 
underwent bariatric surgery. A protocol intraoperative 
liver biopsy was performed on all patients for 
histological phenotyping. Patients with alcohol intake 
>20 g/d and those with other liver diseases based on 
positive disease-specific serological tests and suggestive 
liver histology were excluded. Patients using drugs 
associated with NAFLD prior to liver biopsy were 
excluded [22, 24]. An experienced pathologist read the 
liver biopsy according to the NIH NASH Clinical 
Research Network working group system [34]. 
Genome-wide transcriptome analysis in the 54 samples 
in this study was performed previously [22].  
 
Han Chinese samples: Blood samples for 
ultrasonography-defined NAFLD patients (N = 384) 
and healthy controls (N = 384) were collected in the 
health examination center of Shanghai Jiaotong 
University Affiliated Hospital (Shanghai, China) based 
on a previously study approved by the Shanghai 
Jiaotong University Affiliated Hospital [26]. The 



























defined by the Chinese National Consensus Workshop 
on Nonalcoholic Fatty Liver Disease [35]. Detailed 
information for this community-based cohort was 
described previously [26]. Briefly, physical 
examination, ultrasound screening, medical history 
review, questionnaire-based survey for diet, smoking 
and alcohol intake, as well as biochemical laboratory 
tests were performed. Cases with known causes of 
steatosis, e.g. heavy alcohol intake (> 20 g/day), the use 
of medications/herbals known to contribute to hepatic 
steatosis, as well as hepatitis B and C virus infection 
were excluded. Patients with high likelihood to have 
other known liver diseases including autoimmune 
disease and primary biliary cirrhosis based on 
aforementioned information were also excluded. The 
case and control groups were matched for age and 
gender with both consisted of 229 males and 155 
females, as well as a mean age and standard deviation 
(SD) of 45 ± 13 years.  
 
The study populations were summarized in Table 5. 
 
eQTL mapping for PNPLA3 
 
The liver sample set (N = 206) used to perform eQTL 
mapping has been described in our previous study [21] 
(Table 5). Briefly, genotyping and transcriptome 
profiling on these samples were performed on the 
Illumina Human 610 quad beadchip platform 
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(GEO accession: GSE28893). Genotype imputation was 
conducted with IMPUTE2 program [36] after 
prephasing the genotypes with SHAPEIT [37] using the 
HAPMAP release 27 as a reference to obtain genotypes 
for a total of over 3.9 million SNPs. Standard quality 
control (QC) process was performed by assessing 
SNP/sample call rates, minor allele frequency (removal 
of SNPs with frequency < 15%), deviation from Hardy-
Weinberg equilibrium (p < 0.001), identity-by-decent 
analysis, sex imputation for each sample, etc., as 
previously described  [21, 38]. Age, gender and the first 
3 components of the principal component analysis 
(PCA) for quantifying the ancestry of samples were 
included as covariates for eQTL mapping. We also 
employed the probabilistic estimation of expression 
residuals (PEER) framework [39] to quantifying 
unknown hidden factors. To perform the PNPLA3 gene 
eQTL mapping, we focused only on the cis-acting 
eQTLs within the ±1Mb region of PNPLA3 gene. The 
eQTL mapping was performed using the --assoc 
function for quantitative traits in PLINK [40], which 
correlates allele dosage with changes in the trait. False 
discovery rate (FDR) was used for adjusting the 
multiple testing [41]. Plotting of the p values of SNPs 




Genotyping of rs738409 and rs139051 in DNA samples 
were performed using Taqman assays according to the 
instructions provided by the manufacturer (Life 
Technologies, CA, USA). 
 
Electrophoresis Mobility Shift Assay (EMSA) 
 
EMSA assay was performed according to our protocol 
published previously [43]. Briefly, HepG2 cells were 
cultured in standard conditions and collected for both 
nuclear and cytoplasmic protein extraction using a NE-
PER Nuclear and Cytoplasmic Extraction Kit 
commercial kit (Thermal Scientific, IL, USA). EMSA 
was performed with 2.5µg of total nuclear or 
cytoplasmic extracts using a LightShift Chemi-
luminescent EMSA Kit (Thermal Scientific). 
Biotinylated probe sequences for rs139051 A and G 
alleles were Biotin/GGGTGCTCTCGCCTATAACTTC 
TCTCTCCT and Biotin/GGGTGCTCTCGCCTGTAAC 
TTCTCTCTCCT, respectively. Non-biotin labeled 
probes in a higher concentration (200×) than the labeled 
probes were used as competitors. EMSA bands were 
visualized by exposed to the CL-XPosure film (Thermal 
Scientific) for 3 min. Films were then scanned and the 
intensity of the band interested was quantified using the 
ImageJ software [44]. EMSA assays were 
independently performed three times. 
Haplotype estimation and diplotype assignment 
 
Haplotype frequency between rs139051 and rs738409 
among the eQTL mapping population as well as the 
diplotype for each individual were estimated and 
assigned by using PHASE [45] under default settings. 
To plot the data, samples with the diplotype assignment 




Linkage disequilibrium and haplotype analyses between 
rs139051, rs738409 and rs2294918 in HapMap samples 
(CEU, HCB+JPT and YRI) were performed using 
Haploview 4.2 [46]. Comparisons of gene expression 
level between genotypes were conducted using one-way 
ANOVA, and the comparison for allelic binding 
efficiency in EMSA assays was conducted with 
unpaired t-test based on the data collected from three 
independent experiments. Association between diabetes 
and NAFLD or PNPLA3 mRNA expression and 
interaction between polymorphisms and diabetes was 
examined using linear (for quantitative phenotypes) or 
logistic (for binary phenotypes) regression analysis 
within the R package.The genetic association between 
SNPs or haplotype and NAFLD or NAFLD-related 
phenotypes (including the effect of adding one SNP to a 
model that already included the effect of the other SNP) 
was analysed using the software programs R, PLINK 
[40] and UNPHASED [47, 48]. The same programs 
were used for the multivariate test for inter-dependence 
between rs139051 and the remaining significant eQTLs. 
Univariate comparisons of gene expression between 
genotypes/diplotypes were performed using a t-test or 
ANOVA test. Data plotting was carried out using 





eQTL: expression quantitative trait loci; NAFLD: 
nonalcoholic fatty liver disease; PNPLA3: patatin-like 
phospholipase domain-containing protein 3; SNP: 
single nucleotide polymorphism; mRNA: messenger 
ribosomal nucleic acid; EMSA: electrophoretic mobility 
shift assay; HCC: hepatocellular carcinoma; GWAS: 
Genome-wide association studies; NASH: nonalcoholic 
steatohepatitis; FDR: false discovery rate; NAS: 
NAFLD Activity Score; ChIP-seq: chromatin immuno-
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